CA2934850C - Methods and reagents for radiolabeling - Google Patents

Methods and reagents for radiolabeling Download PDF

Info

Publication number
CA2934850C
CA2934850C CA2934850A CA2934850A CA2934850C CA 2934850 C CA2934850 C CA 2934850C CA 2934850 A CA2934850 A CA 2934850A CA 2934850 A CA2934850 A CA 2934850A CA 2934850 C CA2934850 C CA 2934850C
Authority
CA
Canada
Prior art keywords
compound
formula
nitrogen
sulfur
oxygen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2934850A
Other languages
English (en)
French (fr)
Other versions
CA2934850A1 (en
Inventor
Stefan O. OCHIANA
Nagavarakishore Pillarsetty
Tony Taldone
Gabriela Chiosis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of CA2934850A1 publication Critical patent/CA2934850A1/en
Application granted granted Critical
Publication of CA2934850C publication Critical patent/CA2934850C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/22—Tin compounds
    • C07F7/2208—Compounds having tin linked only to carbon, hydrogen and/or halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA2934850A 2013-12-23 2014-12-23 Methods and reagents for radiolabeling Active CA2934850C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361919901P 2013-12-23 2013-12-23
US61/919,901 2013-12-23
PCT/US2014/072090 WO2015138039A1 (en) 2013-12-23 2014-12-23 Methods and reagents for radiolabeling

Publications (2)

Publication Number Publication Date
CA2934850A1 CA2934850A1 (en) 2015-09-17
CA2934850C true CA2934850C (en) 2022-12-06

Family

ID=54072256

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2934850A Active CA2934850C (en) 2013-12-23 2014-12-23 Methods and reagents for radiolabeling

Country Status (13)

Country Link
US (3) US9994573B2 (enExample)
EP (1) EP3086792B1 (enExample)
JP (1) JP6491214B2 (enExample)
KR (1) KR102325454B1 (enExample)
CN (1) CN106456645B (enExample)
AU (1) AU2014386214B2 (enExample)
BR (1) BR112016014758A8 (enExample)
CA (1) CA2934850C (enExample)
IL (1) IL246403B (enExample)
MX (1) MX2016008418A (enExample)
RU (1) RU2016128528A (enExample)
TW (1) TWI673279B (enExample)
WO (1) WO2015138039A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015138039A1 (en) 2013-12-23 2015-09-17 Memorial Sloan-Kettering Cancer Center Methods and reagents for radiolabeling
MX387627B (es) * 2014-09-17 2025-03-18 Memorial Sloan Kettering Cancer Center Formación de imágenes de inflamación e infección dirigida a hsp90 y terapia
WO2017002196A1 (ja) * 2015-06-30 2017-01-05 株式会社日立国際電気 整合器及び整合方法
KR102175125B1 (ko) * 2018-12-28 2020-11-05 울산과학기술원 미토콘드리아 표적 Hsp90 억제제 기반 화합물 및 이를 포함하는 광역학 치료를 위한 약학적 조성물
WO2022182731A1 (en) * 2021-02-24 2022-09-01 Samus Therapeutics, Inc. Sn-labeling and radiolabeling of epichaperome inhibitors

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
JP2594486B2 (ja) 1991-01-15 1997-03-26 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US20070178537A1 (en) * 2003-06-30 2007-08-02 Sloan-Kettering Institute For Cancer Research Assays for detection of bioactive compounds that interact with heat shock protein 90
US7834181B2 (en) 2005-02-01 2010-11-16 Slaon-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
US9403828B2 (en) 2005-02-01 2016-08-02 Sloan-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
WO2007134298A2 (en) 2006-05-12 2007-11-22 Myriad Genetics, Inc. Therapeutic compounds and their use in cancer
WO2008005937A2 (en) 2006-06-30 2008-01-10 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases through inhibiton of hsp90
KR101313804B1 (ko) 2007-03-20 2013-10-01 쿠리스 인코퍼레이션 Ｈｓｐ９０ 억제제로서의 융합된 아미노 피리딘
NZ586129A (en) 2007-11-14 2012-06-29 Myrexis Inc Therapeutic compounds and their use in treating diseases and disorders
JP5941407B2 (ja) 2009-10-07 2016-06-29 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ Ｈｓｐ９０阻害剤
CN103596955B (zh) 2011-04-05 2016-11-16 索隆-基特林癌症研究协会 Hsp90抑制剂
JP6266506B2 (ja) 2011-04-05 2018-01-24 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ Ｈｓｐ９０阻害物質
BR112013027448A2 (pt) 2011-04-28 2020-09-01 Sloan-Kettering Institute For Cancer Research terapia de combinação com hsp90
EA201490230A1 (ru) 2011-07-08 2014-06-30 Слоан-Кеттеринг Инститьют Фор Кэнсер Рисерч Применение меченых ингибиторов hsp90
EP2972394A4 (en) * 2013-03-15 2016-11-02 Sloan Kettering Inst Cancer HSP90-DESIGNING AND THERAPY
SG11201601542SA (en) 2013-08-16 2016-04-28 Sloan Kettering Inst Cancer Selective grp94 inhibitors and uses thereof
WO2015138039A1 (en) 2013-12-23 2015-09-17 Memorial Sloan-Kettering Cancer Center Methods and reagents for radiolabeling
MX387627B (es) 2014-09-17 2025-03-18 Memorial Sloan Kettering Cancer Center Formación de imágenes de inflamación e infección dirigida a hsp90 y terapia
US20180280397A1 (en) 2015-10-05 2018-10-04 Memorial Sloan Kettering Cancer Center Rational combination therapy for the treatment of cancer

Also Published As

Publication number Publication date
EP3086792B1 (en) 2022-10-12
BR112016014758A8 (pt) 2020-06-02
US20200017502A1 (en) 2020-01-16
IL246403B (en) 2020-08-31
US20170029426A1 (en) 2017-02-02
TWI673279B (zh) 2019-10-01
RU2016128528A (ru) 2018-01-30
BR112016014758A2 (enExample) 2017-08-08
AU2014386214B2 (en) 2020-05-21
JP6491214B2 (ja) 2019-03-27
EP3086792A4 (en) 2017-05-24
US20180251461A1 (en) 2018-09-06
MX2016008418A (es) 2017-01-11
CN106456645A (zh) 2017-02-22
AU2014386214A1 (en) 2016-07-14
WO2015138039A1 (en) 2015-09-17
EP3086792A1 (en) 2016-11-02
CN106456645B (zh) 2021-03-23
KR102325454B1 (ko) 2021-11-16
US9994573B2 (en) 2018-06-12
CA2934850A1 (en) 2015-09-17
US10329293B2 (en) 2019-06-25
KR20160101186A (ko) 2016-08-24
US10793570B2 (en) 2020-10-06
IL246403A0 (en) 2016-08-31
TW201609773A (zh) 2016-03-16
JP2017502039A (ja) 2017-01-19

Similar Documents

Publication Publication Date Title
US10793570B2 (en) Methods and reagents for radiolabeling
AU2016202601B2 (en) Bruton's Tyrosine Kinase Inhibitors
CN113666923A (zh) 烷氧基烷基取代杂环基类抑制剂及其制备方法和应用
CN115175908A (zh) 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用
JP2025528779A (ja) Ｐｄｅ４ｂ阻害剤及びその用途
CA3007993C (en) Inhibitors of bruton's tyrosine kinase and methods of their use
WO2012058645A1 (en) Heterocyclic tyrosine kinase inhibitors
AU2018291688B2 (en) Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections
JP2025518252A (ja) Ｂｃｌ６を阻害又は分解する化合物及びその医薬的な応用
WO2011050284A1 (en) Pyrazolylpyridine antiviral agents
NZ747061A (en) Prodrug of amino acid derivative
CA3226162A1 (en) Aryl compounds and pharmaceutical compositions that modulate ikzf2
JP2024539922A (ja) ピリジル含有化合物
CN113045569B (zh) 用作ret激酶抑制剂的化合物及其应用
ES2971502T3 (es) Inhibidores de ABHD12 y procedimientos de producción y uso de los mismos
BR112016017981B1 (pt) Compostos derivados de azaindola, inibidor de jak3, composição farmacêutica e agente compreendendo ditos compostos, e uso dos mesmos para tratar uma doença que envolve jak3
CN116783198B (zh) 螺环jak抑制剂、含其的药物组合物及其应用
CA3235475A1 (en) Process
HK40105472A (zh) 用作cdk4激酶抑制剂的化合物及其应用
CN113461700A (zh) 一种氧气促进的去芳香化反应在构建螺环二烯酮骨架中的应用

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20191220

H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20250627

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20251106